The 49th issue of the 49th issue of the "Pharmaceutical Adverse Reactions Information Report" recently released by the State Drug Administration (hereinafter referred to as "Notes"),Reminder to follow & ldquo; Aurbroxide injection & rdquo;。

    China Resources Shuanghe (600062.SH)、Chinese Medicine Shares (600511.SH)、Kang Enbei (600572.SH)、Three Essence Pharmaceutical (600829.SH)、Luo Xin Pharmaceutical (08058.HK)、Ta Ling Pharmaceutical (01011.HK)、Fuhe Group (00923.HK)、Lijun International (02005.HK) and many other A -share or Hong Kong stock listed companies are involved。

    It is worth noting is,The State Drug Administration did not put forward the opinions of the above drugs in the "Notes",Only proposed & ldquo; Related manufacturers should strengthen the monitoring of adverse reactions after the drug listing and actively carry out quality research & rdquo;。

    This,A researcher in the pharmaceutical industry admits to this reporter,& ldquo; The amount of these companies produced above is relatively small,Even if you want to recall,Its influence is also stake betting appvery My stake betting applimited,But if it involves the patient's claim for drug problems,The question can be big or small。& rdquo;

    Pharmaceutical companies have no problems

    "Notice" display,Aurbroxide injections are widely used clinically,It is mainly used for acute and chronic respiratory diseases、Premature babies and neonatal respiratory distress syndrome and postoperative pulmonary complications preventive treatment。

    2011,Case Report Database of National Pharmaceutical Adverse Reaction Monitoring Center,Report a total of 2973 cases for reports on adverse reactions on the drug hydrochloride injection drugs/event cases,Among them, 169 cases reported in severe cases。In severe cases,79 cases are children's cases (accounting for 46.75%)。

    A researcher in the pharmaceutical industry in the securities firm told reporters,He also noticed the "Notice",& ldquo; At present,Aurbroxide injection does have certain safety hazards,If there are many cases of severe allergic reactions,So the future application of such drugs will be greatly affected。& rdquo;

    According to an introduction,At present, many varieties such as the amroar hydrochloride injections such as hydrochloride hydrochloride injection。

    The reporter found it in the Database of the State Drug Administration,A total of 7 pharmaceutical companies in China hold 12 amrooral hydrochloride injection production batch number。Where,Condonbe holds two specifications of two specifications of amphibling hydrochloride injections, approved number,respectively & ldquo; Chinese medicine quasi -character H20123225 & rdquo; and & ldquo; Chinese medicine quasi -word H20103773 & rdquo;。

    The Secretary of Kang Enbei Yang Junde told this reporter,The announcement of the Drug Administration has been seen,But the impact on the company is very small,& ldquo; In 2011, the company sold more than 1.9 million yuan of amphitide hydrochloride injections,accounting stake online sports bettingstake sports betting appfor 0.09%of the total sales of the entire sales,less than 1%。January to August this year,The total sales of this product are only 1.8 million yuan,The impact is very small,So it is not enough to clarify the degree of the announcement & rdquo;。

    Drug adverse reactions reproduce multiple A and H listed companies

    In the company’s self -examination,Yang Junde said that there is no case of allergic cases,& ldquo; Nor did it get feedback from other units,The medicine that explains the problem is not produced by Kang Enbei,After all, there are many manufacturers who produce this injection。& rdquo;

    Guorui Pharmaceutical Co., Ltd. of Guorui Pharmaceutical Co., Ltd., a subsidiary of Guorui Pharmaceutical Co., Ltd.,is & ldquo; Chinese medicine quasi -word H20113358 & rdquo;。In addition,Tianjin Pharmaceutical Research Institute Pharmaceutical Co., Ltd.、Yunnan Longhai Natural Botanical Pharmaceutical Co., Ltd. and other companies also hold the product number。

    This,Director and Deputy General Managing Director and Secretary of China Medicine Lu Zhiyuan told reporters,This injection sold only 160,000 yuan last year,& ldquo; In the first half of this year, only 1.75 million yuan was sold,It has a small impact on the overall sales of the company,And,We did not find a case of allergies in self -examination.。

    Another,China Resources Shuanghe wholly -owned subsidiary Anhui Shuanghe Pharmaceutical Co., Ltd.,and Sanji Drug Holding 70%of Harbin Sanjing Ai Fuxi Pharmaceutical Co., Ltd.,All hold 2 approval number,& ldquo; State medicine accurate characters h20052685 & rdquo; and & ldquo; Chinese medicine quasi -word h20050165 & rdquo;,and & ldquo; Chinese medicine quasi -word h20041856 & rdquo; and & ldquo; Chinese medicine quasi -word H20041857 & rdquo;。

    and was suspended censorship & rdquo; IPO Zhejiang Shapi Aisi Pharmaceutical Co., Ltd. also held 2 approval number,& ldquo; Chinese medicine quasi -character h20041116 & rdquo; and & ldquo; Chinese medicine quasi -word H20060449 & rdquo;。

    stake betting appStake Sports BettingHong Kong stock companies also & ldquo; shot & rdquo;

    Actually,Except A -share related listed companies,Hong Kong stock marketing pharmaceutical companies are not spared。

    According to data disclosed by the State Drug Administration,Luo Xin Pharmaceuticals in Hong Kong and Suzhou Pharmaceutical Co., Ltd., a subsidiary of Luo Xin Pharmaceutical and Ta Ling Pharmaceutical, also involved in it。

    Luo Xin Pharmaceutical, who went to Hong Kong in Hong Kong as early as 2005,Currently holding two specifications & ldquo; Entry of Aurium hydrochloride & rdquo; approval number,& ldquo; State medicine quasi -character h20090043 & rdquo; and & ldquo; Chinese medicine quasi -word H20051402 & rdquo;。This time,Suzhou No. 1 Pharmaceutical also holds two & ldquo; Entry of Aurium hydrochloride & rdquo; approval number,& ldquo; Chinese medicine quasi -character h20060154 & rdquo; and & ldquo; Chinese medicine quasi -word h20060155 & rdquo;。

    At the same time,Database of the State Drug Administration also displayed,A total of 19 pharmaceutical companies in China hold 37 & ldquo; Auroxyl hydrochloride injection & rdquo; production batch number。

    Among them, Fuhe Group subsidiary Heilongjiang Fuhe Huaxing Pharmaceutical Group Co., Ltd. holds two approval number,& ldquo; Chinese medicine quasi -character h20061249 & rdquo; and & ldquo; Chinese medicine quasi -word H20041024 & rdquo;。

    Shijiazhuang Four Pharmaceutical Co., Ltd., a subsidiary of Lijun International, also has two approval numbers,& ldquo; Chinese medicine quasi -character h20103376 & rdquo; and & ldquo; Chinese medicine quasi -word h20103372 & rdquo;。

    & ldquo; You can't determine this medicine if you are sure that there must be problems,Just their products also belong to the amphibly hydrochloride injection preparation。& rdquo; The above -mentioned pharmaceutical researcher believes,The State Drug Administration just reminds the allergic reactions that this drug may bring,but does not mean that companies that produce this medicine have drug problems。

    For the hydrochloride injection preparation product that has been sold now,The directors of Kang Enbei and the Chinese Medicine shares stated that due to the My stake betting appstake betting appsmall sales,No allergic case,Therefore, there is no need to recall。